In conclusion, in this post hoc exploratory analysis of the IRONMAN trial, there was a trend to a greater increase in haemoglobin with intravenous ferric derisomaltose in iron‐deficient patients with heart failure taking an SGLT2 inhibitor. This evidence concerns the gene SLC5A2 and heart failure.